Cytek Biosciences (CTKB) Revenue (2020 - 2026)

Cytek Biosciences has reported Revenue for 7 years, with the latest figure at $44.1 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 6.46% year-over-year to $44.1 million; the trailing twelve-month figure through Mar 2026 stood at $204.2 million (up 3.61% YoY), and the FY2025 full-year result was $201.5 million, up 0.52% from the prior year.
• Revenue for Q1 2026 stood at $44.1 million, down from $62.1 million in the prior quarter.
• The five-year high for Revenue was $62.1 million in Q4 2025, with the low at $35.1 million in Q1 2022.
• Historically, Revenue has averaged $47.2 million across 5 years, with a median of $46.6 million in 2024.
• Annual changes were most pronounced in 2022 — Revenue soared 155.64% — and 2025, when it fell 7.59%.
• Cytek Biosciences' Revenue stood at $48.3 million in 2022, then advanced by 20.48% to $58.2 million in 2023, then decreased by 1.3% to $57.5 million in 2024, then increased by 8.12% to $62.1 million in 2025, then dropped by 28.98% to $44.1 million in 2026.
• The last three Revenue figures came in at $44.1 million (Q1 2026), $62.1 million (Q4 2025), and $52.3 million (Q3 2025), per Business Quant data.